Plasmodium falciparum-infected mice: more than a tour de force

Trends in Parasitology

Volumn 23, Issue 6, 2007, Pages 254-259

  Moreno, Alicia ^a,b,c   Pérignon, Jean Louis ^d   Morosan, Serban ^e   Mazier, Dominique ^a,b,c   Benito, Agustin ^f  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d INSTITUT PASTEUR   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Red de Investigación de Centros de Enfermedades Tropicales RICET Madrid   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; VACCINE;

ANIMAL MODEL; ARTICLE; CHIMERA; DISEASE MODEL; EXPERIMENTAL MODEL; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; MALARIA; MOUSE; MOUSE STRAIN; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; TRANSGENIC MOUSE;

ANIMALS; CHIMERA; DISEASE MODELS, ANIMAL; ERYTHROCYTES; HUMANS; MALARIA, FALCIPARUM; MICE; MICE, INBRED NOD; MICE, SCID; PLASMODIUM FALCIPARUM;

ANIMALIA; MUS; PLASMODIUM FALCIPARUM;

EID: 34248663532     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2007.04.004     Document Type: Article

References (44)

1. Trager W., and Jensen J.B. Human malaria parasites in continuous culture. Science 193 (1976) 673-675
2. Mazier D., et al. Complete development of hepatic stages of Plasmodium falciparum in vitro. Science 227 (1985) 440-442
3. Meis J.F., et al. Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Exp. Parasitol. 70 (1990) 1-11
4. Hernandez-Valladares M., et al. Genetic resistance to malaria in mouse models. Trends Parasitol. 21 (2005) 352-355
5. Carlton J.M., et al. Of mice and malaria mutants: unravelling the genetics of drug resistance using rodent malaria models. Trends Parasitol. 17 (2001) 236-242
6. Medana I.M., and Turner G.D. Human cerebral malaria and the blood-brain barrier. Int. J. Parasitol. 36 (2006) 555-568
7. Lou J., et al. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin. Microbiol. Rev. 14 (2001) 810-820
8. Fidock D.A., et al. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3 (2004) 509-520
9. Ishihara C., et al. Mannan decelerates the clearance of human red blood cells in SCID mouse. Immunopharmacology 38 (1998) 223-228
10. Ishihara C., et al. Transfusion with xenogeneic erythrocytes into SCID mice and their clearance from the circulation. J. Vet. Med. Sci. 56 (1994) 1149-1154
11. Sacci Jr. J.B., et al. Mouse model for exoerythrocytic stages of Plasmodium falciparum malaria parasite. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3701-3705
12. Tsuji M., et al. Establishment of a SCID mouse model having circulating human red blood cells and a possible growth of Plasmodium falciparum in the mouse. Vaccine 13 (1995) 1389-1392
13. Butcher G.A., et al. The SCID mouse as a laboratory model for development of the exoerythrocytic stages of human and rodent malaria. Exp. Parasitol. 77 (1993) 257-260
14. Badell E., et al. Human Plasmodium liver stages in SCID mice: a feasible model?. Parasitol. Today 11 (1995) 169-171
15. Badell E., et al. A mouse model for human malaria erythrocytic stages. Parasitol. Today 11 (1995) 235-237
16. Moore J.M., et al. Maintenance of the human malarial parasite, Plasmodium falciparum, in SCID mice and transmission of gametocytes to mosquitoes. J. Exp. Med. 181 (1995) 2265-2270
17. Rajan T.V., et al. Immunodeficient mice as hosts for hemoparasitic infections. Parasitol. Today 12 (1996) 479-485
18. Sacci J.B., et al. Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers. Int. J. Parasitol. 36 (2006) 353-360
19. Morosan S., et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J. Infect. Dis. 193 (2006) 996-1004
20. Moreno Sabater A., et al. Experimental infection of immunomodulated NOD/LtSz-SCID mice as a new model for Plasmodium falciparum erythrocytic stages. Parasitol. Res. 95 (2005) 97-105
21. Moreno A., et al. The course of infections and pathology in immunomodulated NOD/LtSz-SCID mice inoculated with Plasmodium falciparum laboratory lines and clinical isolates. Int. J. Parasitol. 36 (2006) 361-369
22. Moreno A., et al. Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies. Antimicrob. Agents Chemother. 45 (2001) 1847-1853
23. Badell E., et al. Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J. Exp. Med. 192 (2000) 1653-1660
24. Druilhe P., et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2 (2005) e344
25. Macchiarini F., et al. Humanized mice: are we there yet?. J. Exp. Med. 202 (2005) 1307-1311
26. Lawrence M.B., and Springer T.A. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65 (1991) 859-873
27. Murray A.G., et al. Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9146-9150
28. Ho M., et al. Visualization of Plasmodium falciparum-endothelium interactions in human microvasculature: mimicry of leukocyte recruitment. J. Exp. Med. 192 (2000) 1205-1211
29. Yipp B.G., et al. Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of clinical Plasmodium falciparum isolates in vivo. Blood 101 (2003) 331-337
30. Yipp B.G., et al. Src-family kinase signaling modulates the adhesion of Plasmodium falciparum on human microvascular endothelium under flow. Blood 101 (2003) 2850-2857
31. Chakravorty S.J., and Craig A. The role of ICAM-1 in Plasmodium falciparum cytoadherence. Eur. J. Cell Biol. 84 (2005) 15-27
32. Andriole G.L., et al. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J. Immunol. 135 (1985) 2911-2913
33. Bosma G.C., et al. A severe combined immunodeficiency mutation in the mouse. Nature 301 (1983) 527-530
34. Shultz L.D., et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154 (1995) 180-191
35. Shultz L.D., et al. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J. Immunol. 164 (2000) 2496-2507
36. Soderstrom I., et al. Establishment and characterization of RAG-2 deficient non-obese diabetic mice. Scand. J. Immunol. 43 (1996) 525-530
37. + T cell engraftment in β2-microglobulin-deficient NOD-SCID mice. J. Immunol. 158 (1997) 3578-3586
38. Ishikawa F., et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain (null) mice. Blood 106 (2005) 1565-1573
39. Nicolini F.E., et al. NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia 18 (2004) 341-347
40. Punzon I., et al. Highly efficient lentiviral-mediated human cytokine transgenesis on the NOD/SCID background. Blood 103 (2004) 580-582
41. Heckel J.L., et al. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62 (1990) 447-456
42. Mercer D.F., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7 (2001) 927-933
43. van Rooijen N., and van Kesteren-Hendrikx E. In vivo depletion of macrophages by liposome-mediated "suicide". Methods Enzymol. 373 (2003) 3-16
44. + Th2 response in BALB/c mice infected with Leishmania major. J. Immunol. 165 (2000) 2628-2636